Presence of Helicobacter Species in Gastric Mucosa of Human Patients and Outcome of Helicobacter Eradication Treatment

• Type: Article in International Scientific Journal
• Date: 2022

Authors

Matos, R (Author) Other; Taillieu, E (Author) Other; De Bruyckere, S (Author) Other; De Witte, C (Author) Other; Rema, A (Author) Other; Santos Sousa, H (Author) FMUP; Nogueiro, J (Author) Other; Reis, CA (Author) Other; Carneiro F (Author) FMUP; Haesebrouck, F (Author) Other; Amorim, I (Author) Other; Gaertner, F (Author) Other

Journal

The Journal is awaiting validation by the Administrative Services.

Title: JOURNAL OF PERSONALIZED MEDICINE

Vol. 27

Final page: 181

ISSN: 2075-4426

Publisher: MDPI

Indexing

ISI Web of Knowledge - 6 Citations

Scopus - 4 Citations

Other information

Authenticus ID: P-00W-1FT

DOI: 10.3390/jpm12020181

Abstract (EN): The genus Helicobacter is composed of bacteria that colonize both the human and animal gastrointestinal tract. Helicobacter pylori infects half of the world's population, causing various disorders, such as gastritis, duodenitis and gastric cancer. Additionally, non-Helicobacter pylori Helicobacter species (NHPH) are commonly found in the stomach of pigs, dogs and cats. Most of these species have zoonotic potential and prevalence rates of 0.2-6.0%, and have been described in human patients suffering from gastric disorders undergoing a gastric biopsy. The aim of this study was to determine the occurrence of Helicobacter spp. in the stomach of patients with gastric cancer (n = 17) and obese (n = 63) patients. Furthermore, the outcome of the Helicobacter eradication treatment and the current infection status was evaluated. Overall, based on the genus-specific PCR followed by sequencing, DNA from Helicobacter spp. was detected in 46.3% of the patients, including single infections with H. pylori in 43.8% of the patients and mixed infections with H. pylori and canine- or feline-associated H. felis in 2.5%. About 32.5% of the patients had been subjected to previous Helicobacter eradication therapy and the triple standard therapy was the most frequent scheme (42.3%). In 48.0% of the patients who received eradication treatment, bacteria were still detected, including one mixed infection. In 23.1% of the patients who reported that a subsequent test had been performed to confirm the elimination of the bacteria, Helicobacter were still detected. In conclusion, although in a smaller percentage, NHPH may also be present in the human stomach. Thus, specific NHPH screening should be included in the diagnostic routine. The continued presence of H. pylori in the stomach of patients recently subjected to eradication schemes raises questions about the efficacy of the current Helicobacter treatments.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 13